A number of other equities analysts have also issued reports on the company. Zacks Investment Research lowered Zoetis from a hold rating to a sell rating and set a $83.00 price target on the stock. in a report on Saturday, January 13th. Morgan Stanley raised Zoetis from an equal weight rating to an overweight rating and set a $80.00 price target on the stock in a report on Wednesday, November 29th. Jefferies Group reissued a buy rating on shares of Zoetis in a report on Friday, November 10th. Craig Hallum reissued a buy rating and set a $85.00 price target (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, BidaskClub raised Zoetis from a hold rating to a buy rating in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of Buy and an average price target of $80.00.
Zoetis (NYSE ZTS) opened at $79.73 on Thursday. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a twelve month low of $52.25 and a twelve month high of $81.40. The stock has a market capitalization of $38,850.00, a PE ratio of 36.57, a P/E/G ratio of 1.69 and a beta of 1.07.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is presently 22.94%.
Institutional investors and hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd lifted its position in shares of Zoetis by 7.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after acquiring an additional 401 shares during the period. Robecosam AG lifted its position in shares of Zoetis by 4.6% during the 4th quarter. Robecosam AG now owns 15,346 shares of the company’s stock valued at $1,111,000 after acquiring an additional 679 shares during the period. Daiwa Securities Group Inc. lifted its position in shares of Zoetis by 4.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after acquiring an additional 697 shares during the period. Sandy Spring Bank lifted its position in shares of Zoetis by 2.3% during the 4th quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after acquiring an additional 708 shares during the period. Finally, Penserra Capital Management LLC lifted its position in shares of Zoetis by 18.6% during the 4th quarter. Penserra Capital Management LLC now owns 4,550 shares of the company’s stock valued at $327,000 after acquiring an additional 715 shares during the period. 93.72% of the stock is currently owned by institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.